Expression of gene MAGE-A4 in Reed-Sternberg cells

Blood

Volumn 95, Issue 11, 2000, Pages 3530-3533

  Chambost, Hervé ^b   Van Baren, Nicolas ^b   Brasseur, Francis ^b   Godelaine, Danièle ^b   Xerri, Luc ^b   Landi, Sylvaine Just ^b   Theate, Ivan ^b   Plumas, Joel ^b   Spagnoli, Guilio C ^b   Michel, Gerard ^b   Coulie, Pierre G ^b   Olive, Daniel ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN;

ARTICLE; CONTROLLED STUDY; GENE; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; LYMPH NODE BIOPSY; LYMPHOMA; MAJOR CLINICAL STUDY; MULTIGENE FAMILY; PRIORITY JOURNAL; REED STERNBERG CELL; SOLID TUMOR;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; HODGKIN DISEASE; HUMANS; LYMPH NODES; LYMPHOCYTES; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MALE; NEOPLASM PROTEINS; REED-STERNBERG CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0034210182     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft versus host disease in human recipients of allogeneic marrow grafts. N Engl J Med. 1979;300:1068.
2. Apperley JF, Jones L, Hale G, Goldman JM. Bone marrow transplant for patients with chronic myeloid leukemia: T cell depletion with Campath-1 reduces the incidence of graft versus host disease but may increase the risk of leukemia relapse. Bone Marrow Transplant. 1988;1:53.
3. Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73:1720.
4. Chopra R, Goldstone AH, Pearce R, et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplantation Group Registry Data. J Clin Oncol. 1992;10:1690.
5. Philipps GL, Herzig RH, Lazarus HM, Fay JW, Griffith R, Herzig GP. High dose chemotherapy, fractionnated total body irradiation and allogeneic transplantation for malignant lymphoma. J Clin Oncol. 1986;4:480.
6. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991;77:649.
7. Nagler A, Ackerstein A, Or R, Naparstek E, Slavin S. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-α in lymphoma patients postautologous marrow or stem cell transplantation Blood. 1997;89:3951.
8. Slavin S, Nagler A. Immunotherapy in conjuction with autologous and allogeneic blood or marrow transplantation in lymphoma. Ann Oncol. 1998;9: S31.
9. Boon T. Human tumor antigens recognized by T lymphocytes. J Exp Med. 1996;183:725.
10. Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, Pelicci P, Parmiani G. Human CD4+ lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein PML-RARα present in acute promyelocytic cells. Blood. 1993;81:1369.
11. Bocchia M, Wentworth PA, Southwood S, et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood. 1995;85:2680.
12. Ten Bosch GJA, Toornviell AC, Friede T, Melief CJM, Leeksma OC. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by in vitro immunization with a BCR-ABL breakpoint peptide. Blood. 1996;88:3522.
13. Nieda M, Nicol A, Kikuchi A, et al. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myelogenous leukemia. Blood. 1998;91:977.
14. Barratt-Boyes SM. Making the most of mucin: a novel target for tumor immunotherapy. Cancer Immunol Immunother. 1998;43:142.
15. Sing AP, Ambinder RF, Hong DJ, et al. Isolation of Epstein-Barr virus specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy for EBV+ Hodgkin's disease. Blood. 1997;89:1978.
16. Van Baren N, Chambost H, Ferrant A, et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol. 1998;102:1376.
17. Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643.
18. De Plaen E, Arden K, Traversari C, et al. Structure, chromosomal localization and expression of 12 genes of the MAGE family. Immunogenetics. 1994;40:360.
19. Türeci O, Chen YT, Sahin U, et al. Expression of SSX genes in human tumors. Int J Cancer. 1998; 77:19.
20. Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLAA1. Int J Cancer. 1999;80:219.
21. Chambost H, Brasseur F, Coulie P, et al. A tumor-associated antigen expression in human haematological malignancies. Br J Haematol. 1993;84: 524
22. Shichijo S, Tsunosue R, Masuoka K, et al. Expression of the MAGE gene family in human lymphocytic leukemia. Cancer Immunol Immunother. 1995;41:95.
23. Shichijo S, Sagawa K, Brasseur F, Boon T, Itoh K. MAGE-1 gene is expressed in T-cell leukemia. Int J Cancer. 1996;65:709.
24. van Baren N, Brasseur F, Godelaine D, et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood. 1999; 94:1156.
25. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361.
26. Davis LG, Dibner MD, Battey JF. Basic Methods in Molecular Biology. New York, NY: Elsevier; 1986.
27. De Smet C, Lurquin C, Van der Bruggen P, De Plaen E, Brasseur F, Boon T. Sequence and expression pattern of the human MAGE-2 gene. Immunogenetics. 1994;39:121.
28. Landry C, Brasseur F, Spagnoli G, et al. Monoclonal antibody B57 stains tumor tissues that express gene MAGE-A4. Int J Cancer. In press.
29. Cossman J, Annunziata CM, Barash S, et al. Reed-Sternberg cell genome expression supports a B-cell lineage. Blood. 1999;94:411.
30. De Plaen E, Naerhuyzen B, De Smet C, Skikora JP, Boon T. Alternative promoters of gene MAGE-4a. Genomics. 1997;40:305.
31. Murray P, Constandinou CM, Crocker J, Young L, Ambinder R. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 sequence in Epstein-Barr virus-positive Hodgkin's disease. Blood. 1998;92:2477.
32. Delabie J, Ceuppens JL, Vandenberghe P, de Boer M, Coorevits L, De Wolf-Peeters C. The B7/ BB1 antigen is expressed by Reed Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines. Blood. 1993;82:2845
33. Van Gool SW, Delabie J, Vandenberghe P, Coorevits L, De Wolf-Peeters C, Ceuppens JL. Expression of B7-2 (CD86) molecules by Reed Sternberg cells of Hodgkin's disease. Leukemia. 1997;11:46.
34. Xerri L, Devilard E, Hassoun J, Olive D, Birg F. In vivo expression of the CTLA4 inhibitory receptor in malignant and reactive cells from human lymphoma. J Pathol. 1997;183:182.
35. Lee SP, Constandinou CM, Thomas WA, et al. Antigen presenting phenotype of Hodgkin Reed Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein-Barr virus-specific cytotoxic T-cell recognition. Blood. 1998;92:1020.